Friday, 17 Jan 2020

You are here

RheumNow Podcast – DESIREABLE Results (5.3.19)

Dr. Jack Cush reviews the latest journal articles and rheumatology news from the past week on RheumNow.com:

  1. FDA has approved Samsung-Bioepsis biosimilar version of etanercept - Eticovo (etanercept-ykro), approved in other countries under names Benepali and Brenzys. Approval based on 596 RA pt trial w/ 52 wk ACR20 of 80.8% and 81.5% (Enbrel arm) https://t.co/r3q9dQ0Bdb
  2. Benlysta is approved for use in pediatric SLE based on the 80 pt PLUTO trial; 1 yr of PBO vs 10 mg/kg belimumab plus standard therapy. Results presented at ACR2018 shows BEL in pediatric SLE to be safe and effective (SRI4 resp 52.8% vs 43.6%). https://t.co/cjqPaWu92O.     
  3. Analysis of new drug registration trials in RA (1998-2018) shows an increase in placebo responses (significant for ACR50 & ACR70); yet with significant reductions in Disease duration, SJCand DAS28-ESR. Changes in RA? RCTs? expectation bias? https://buff.ly/2USAjC6 
  4. DESIRABLE study from JAPAN Rx 654 (relatively) early, MTX tx RA pts with PBO, or Prolia given q3 or q6 mos. Denosumab lead to significant reductions in Erosion scores, total Xray (not JSN) and increased BMD (vs PBO); no effect on ACR20/50/70. https://t.co/DQrmXYrhAf   
  5. French real-world study of Psoriatic arthritis pts starting apremilast (n 3207) or MTX (n 2736), finds higher discontinuation rates at 1 yr for apremilast (69%) vs MTX (59%) https://t.co/bhPwaPhX23 
  6. Study of 213 RApatients starting MTX. After mean F/U 4.3 yrs and 6288 ALT tests, 7% had ALT elevation; 21% of these were ALT>1.5×ULN. Strongest predictor was a pre‐treatment elevation of ALT (OR 6). 3% permanently stopped MTX due to ALT elevation. https://t.co/ti4ClypXgQ
  7. Study of 14928 Autoimmune/Rheum Dz pts in UK Clinical Practice Research database found the influenza vaccination was not associated with arthritis flare or increase in PCP visits (actually lowered consultas for joint pain in following 90 days) https://t.co/rrwu68g7DM
  8. 8/171 ANCA-Assoc Vasculitis pts had Uncommon manifestations - often seen in PR3+, very young or very old w/ delay in Dx (~12 mos); includes Pancreatitis, unusual pulmonary dz (cystic lung disease; usual interstitial pneumonia) or splenic infarcts https://t.co/UFONWMTYYi   
  9. Nonadherence is Costly for Patients in Pain   
  10. Ideal Outcomes are Seldom Achieved in Gout   
  11. New ACR/AF Guidelines on JIA Polyarthritis and Uveitis 

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

CDC: 15% of US Adults are Physically Inactivie

All states and territories had more than 15% of adults who were physically inactive and this estimate ranged from 17.3 to 47.7%,  according to new state maps of adult physical inactivity prevalence released today by the Centers for Disease Control and Prevention (CDC).

RheumNow Podcast- The Down Side of Steroids (1.17.20)

Dr. Jack Cush reviews the journal reports and news from RheumNow.com. Be sure to register for RheumNow Live 3/13/2020 in Fort Worth Rheumnow.live.

RheumNow Podcast- Knee Pain Knockout (1.10.20)

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. The podcast covers: best therapies for dactylitis and enthesitis; we have a new knockout for knee pain in OA; and are you on the naughty or nice list when it comes to the new ACR-AF guidelines for arthritis? This and more. Tune in.

2019 Rheumatology Year in Review

2019 was a year marked by major advances, hallmark research, and big news items affecting rheumatology.   Herein you will find our top 10 list, formulated by what I think rheumatologists should know and what will likely change their standards and practice in 2020 and beyond. 

RheumNow Podcast - 2019 Rheumatology Year in Review

Dr. Jack Cush reviews highlights from 2019 on RheumNow.com. Topics covered in this annual review include: superheroes lost; venous thromboembolic events and JAKs; free medical tuition; women in rheumatology; 52 new drug approvals in 2019 and 330 drugs with a 2020 price hike; scleroderma disappointments; novel new treatments and newer tests; the boom of Shingrix; RheumNow.Live - and more.